Edition:
United States

Agilent Technologies Inc (A)

A on New York Consolidated

64.73USD
25 Sep 2017
Change (% chg)

$-1.05 (-1.60%)
Prev Close
$65.78
Open
$65.80
Day's High
$65.90
Day's Low
$64.44
Volume
1,841,833
Avg. Vol
1,886,895
52-wk High
$66.45
52-wk Low
$42.92

Latest Key Developments (Source: Significant Developments)

Agilent Technologies files lawsuit against Shanghai Echrom Electronic and former employees
Tuesday, 22 Aug 2017 11:00pm EDT 

Aug 22 (Reuters) - Agilent Technologies Inc :FILED A CIVIL LAWSUIT AGAINST SHANGHAI ECHROM ELECTRONIC TECHNOLOGY CO LTD AND SEVERAL FORMER EMPLOYEES OF AGILENT.THE SUIT ALSO REQUESTS THE COURT TO ORDER COMPENSATION FOR AGILENT'S LOSSES.AGILENT TECHNOLOGIES INC-LAWSUIT ALLEGING INFRINGEMENT OF TRADE SECRETS AND PETITIONING COURT TO STOP DEFENDANTS' USE OF CO'S PROPRIETARY TECHNOLOGIES.LAWSUIT ALSO REQUESTS COURT TO ORDER COMPENSATION FOR AGILENT'S LOSSES.  Full Article

Agilent Technologies announces board changes
Wednesday, 15 Mar 2017 04:05pm EDT 

Agilent Technologies Inc : Agilent Technologies board of directors elects Koh Boon Hwee as new chairman . Koh Boon, who has been a member of Agilent's board since 2003, replaces James Cullen .James Cullen will continue as a director.  Full Article

Agilent Technologies reports Q1 GAAP EPS $0.52
Tuesday, 14 Feb 2017 04:05pm EST 

Agilent Technologies Inc : Agilent Technologies reports first-quarter 2017 results . Sees FY 2017 non-GAAP earnings per share $2.10 to $2.16 . Q1 non-GAAP earnings per share $0.53 . Q1 GAAP earnings per share $0.52 . Sees Q2 2017 revenue $1.04 billion to $1.06 billion . Sees FY 2017 revenue $4.33 billion to $4.35 billion . Q1 revenue $1.07 billion versus I/B/E/S view $1.05 billion . Sees Q2 2017 non-GAAP earnings per share $0.47 to $0.49 . Q1 earnings per share view $0.49 -- Thomson Reuters I/B/E/S . Q2 earnings per share view $0.49, revenue view $1.05 billion -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $2.13, revenue view $4.33 billion -- Thomson Reuters I/B/E/S.  Full Article

Agilent Technologies, Burning Rock sign agreement on molecular diagnostics
Thursday, 29 Sep 2016 12:00am EDT 

Agilent Technologies Inc : Says Agilent Technologies and Burning Rock sign agreement on molecular diagnostics .Says Burning Rock plans to register its molecular diagnostic kit with China Food And Drug Administration.  Full Article

Agilent Tech sees FY 2016 non-gaap earnings per share $1.89 to $1.91
Wednesday, 17 Aug 2016 04:05pm EDT 

Agilent Technologies Reports Third : Quarter 2016 results . Sees q4 non-gaap earnings per share $0.50 to $0.52 . Q3 non-gaap earnings per share $0.49 from continuing operations . Sees q4 2016 revenue $1.05 billion to $1.07 billion . Sees fy 2016 non-gaap earnings per share $1.89 to $1.91 . Q3 gaap earnings per share $0.38 from continuing operations . Sees fy 2016 revenue $4.14 billion to $4.16 billion . Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S . Q3 earnings per share view $0.47, revenue view $1.05 billion -- Thomson Reuters I/B/E/S . Q4 earnings per share view $0.54, revenue view $1.09 billion -- Thomson Reuters I/B/E/S .Fy2016 earnings per share view $1.91, revenue view $4.18 billion -- Thomson Reuters I/B/E/S.  Full Article

Agilent Technologies to build new facility in Colorado
Tuesday, 9 Aug 2016 08:00pm EDT 

Agilent Technologies Inc : Agilent technologies to build new facility in Colorado, increasing pharmaceutical manufacturing capacity . Expansion to enable co to more than double its commercial manufacturing capacity for nucleic acid active pharmaceutical ingredients Further company coverage: [A.N] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Agilent Technologies posts adj profit of $0.44 from cont ops
Monday, 16 May 2016 04:05pm EDT 

Agilent Technologies : Raises its full-year operating cash flow guidance from $650 million to $740 million . Raises FY guidance for core revenue growth , adjusted non-GAAP operating margin , non-GAAP earnings per share, operating cash flow . No change to FY capital expenditure guidance of $140 million . Q2 net revenue $1,019 million . Q3 earnings per share view $0.47, revenue view $1.04 billion -- Thomson Reuters I/B/E/S . Fy2016 earnings per share view $1.86, revenue view $4.13 billion -- Thomson Reuters I/B/E/S . Quarter 2016 results . Sees Q3 non-GAAP earnings per share $0.45 to $0.47 . Sees FY 2016 non-GAAP earnings per share $1.88 to $1.92 . Q2 non-GAAP earnings per share $0.44 from continuing operations . Q2 GAAP earnings per share $0.28 from continuing operations . Sees Q3 2016 revenue $1.03 billion to $1.05 billion . Sees FY 2016 revenue $4.16 billion to $4.18 billion .Q2 earnings per share view $0.39 -- Thomson Reuters I/B/E/S.  Full Article

Enzo Biochem Inc reaches $9 million patent infringement settlement with Agilent Technologies Inc
Wednesday, 6 Jan 2016 08:30am EST 

Enzo Biochem Inc:Has reached and finalized a settlement with Agilent Technologies Inc payment of $9 million to Enzo in an infringement action brought by Enzo regarding its U.S. Patent No. 7,064,197.Says resolved suit involves one of 11 infringement cases brought in delaware federal district court, eight of which remain pending.  Full Article

Protea Biosciences Group, Inc announces Biopharm Industry Collaboration
Tuesday, 8 Dec 2015 08:00am EST 

Protea Biosciences Group, Inc:Says it is collaborating with Agilent Technologies, Inc to address customer challenges within existing Biopharma bioanalytical workflows in order to meet the emerging needs of the growing biopharmaceutical industry.Memorandum of Understanding (MOU), Protea, using Agilent instrumentation combined with its technology, will develop workflows that focus on developing new methods for the field of metabolomics.  Full Article

Agilent Technologies Inc announces cash dividend
Thursday, 19 Nov 2015 04:05pm EST 

Agilent Technologies Inc:Says increased the company's quarterly dividend to 11.5 cents per share of common stock.Paid on Jan. 27, 2016, to all shareholders of record as of the close of business on Jan. 5, 2016.  Full Article

BRIEF-Agilent Technologies receives expanded FDA approval for Dako PD-L1 IHC 22C3 pharmDx

* Agilent Technologies receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in gastric or gastroesophageal junction (GEJ) cancer Source text for Eikon: Further company coverage: